Abstract

Management of Ileal Pouch Cancer in Patients With Inflammatory Bowel Disease.

Wang, Shanshan (S);Ko, Huaibin Mabel (HM);Lukin, Dana J (DJ);Scherl, Ellen (E);Kiran, Ravi (R);Shen, Bo (B);

 
     

Author information

Gastro Hep Adv.2025 Oct 01;5(2):100824.doi:10.1016/j.gastha.2025.100824

Abstract

BACKGROUND AND AIMS: Ileal pouch cancer in patients with inflammatory bowel disease, though rare, represents a significant concern due to the high mortality. While prior studies emphasized incidence and risk factors, this study evaluates the current management and prognosis of pouch cancer following ileal pouch-anal anastomosis.

METHODS: Consecutive patients with pouch cancer were identified from a prospectively maintained database (2019-2025). Patients with familial adenomatous polyposis and precancerous conditions were excluded. Demographic, clinical, endoscopic, and histologic data were collected. Primary outcomes were disease recurrence/progression and oncological survival.

RESULTS: Of 699 patients, 10 developed pouch cancer (incidence: 0.5 per 100 person-years). Lesions were located at the cuff (n = 3), anal transition zone (n = 3), pouch body (n = 2), prepouch ileum (n = 1), and both anal transition zone and pouch body (n = 1). Two patients presented with distant metastases without endoscopically visible lesions in the pouch. The histological types were adenocarcinoma (n = 5), squamous cell carcinoma (n = 3), non-Hodgkin lymphoma (n = 1), and neuroendocrine tumor (n = 1). The diagnosis was established through endoscopic biopsies (n = 2), surgical resection (n = 6; three with prior endoscopically diagnosed dysplasia), and cross-sectional imaging (n = 2). Seven patients had localized disease, allowing curative treatment. Treatments included surgery (n = 5), chemoradiotherapy (n = 6), and lanreotide for neuroendocrine tumor. Over a median follow-up of 2.8 years (interquartile range: 1.5-5.2), recurrence or disease progression occurred in three patients (30%), and one patient (10%) died from pouch cancer, with a 5-year cumulative survival of 88.9%.

CONCLUSION: Adenocarcinoma remains the most common histological type; however, nonadenocarcinoma, especially the squamous cell carcinoma, has been increasingly recognized. Endoscopic surveillance was helpful in detecting precancerous lesions.

© Copyright 2013-2026 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.